Evaluation of a new point-of-care test for influenza A and B in travellers with influenza-like symptoms

Institute of Tropical Medicine and International Health, Charité, University Medicine Berlin, Berlin, Germany.
Clinical Microbiology and Infection (Impact Factor: 5.77). 08/2007; 13(7):665-9. DOI: 10.1111/j.1469-0691.2007.01739.x
Source: PubMed


Point-of-care (POC) tests for influenza facilitate clinical case management, and might also be helpful in the care of travellers who are at special risk for influenza infection. To evaluate influenza POC testing in travellers, a new assay, the ImmunoCard STAT! Flu A and B, was used to investigate travellers presenting with influenza-like symptoms. Influenza virus infection was diagnosed in 27 (13%) of 203 patients by influenza virus-specific PCR and viral culture. The POC test had sensitivity and specificity values of 64% and 99% for influenza A, and 67% and 100% for influenza B, respectively. Combined sensitivity and specificity were 67% and 99%, respectively, yielding positive and negative predictive values of 95%, and positive and negative likelihood ratios of 117 and 0.34, respectively. The convenient application, excellent specificity and high positive likelihood ratio of the POC test allowed rapid identification of influenza cases. However, negative test results might require confirmation by other methods because of limitations in sensitivity. Overall, influenza POC testing appeared to be a useful tool for the management of travellers with influenza-like symptoms.

7 Reads
  • Source
    • "Influenza viruses are spread by small airborne droplets expelled while talking, breathing, and coughing. The most susceptible population is children, and school-age children are the most common spreaders of infection [3-7]. Vaccines are thought to be the most effective modality for influenza control, and phylogenetic analyses of genes of viruses provide valuable information for vaccine development and prophylaxis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: From October 2006 to February 2007, clinical specimens from 452 patients with symptoms related to respiratory tract infection in the northern region of Taiwan were collected. Real-time PCR and direct immunofluorescent antibody tests showed that 145 (32%) patients had influenza B virus infections. Subsequently, nucleotide sequence analyses of both hemagglutinin (HA) and neuraminidase (NA) genes of 39 isolates were performed. Isolated viruses were antigenically characterized using hemagglutinin inhibition (HI) test. Phylogenetic tree analysis showed that all the isolates belonged to the B reassortant lineage with HA gene belonged to the B/Victoria/2/87 lineage and the NA gene belonged to the B/Yamagata/16/88 lineage. In addition, a group of children aged between 6 to 8 years old resided in Yilan county were infected with a variant strain. Hemagglutinin inhibition (HI) tests confirmed that all the reassortant influenza B viruses were B/Malaysia/2506/04-like viruses. Pre- and post-immunized serum samples from 4 normal volunteers inoculated with 2007 influenza vaccine were evaluated for their HI activity on 6 reassortant B isolates including two variants that we found in the Yilan county. The results demonstrated that after vaccination, all four vaccinees had at least 4-fold increases of their HI titers. The results indicate that the 2006-2007 seasonal influenza vaccine was effective in stimulating protective immunity against the influenza B variants identified in Yilan county. Continuous surveillance of emerging influenza B variants in the northern region of Taiwan is important for the selection of proper vaccine candidate in the future.
    BMC Research Notes 02/2009; 2(1):86. DOI:10.1186/1756-0500-2-86
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: As the world prepares for the next influenza pandemic, governments have made significant funding commitments to vaccine development and antiviral stockpiling. While these are essential components to pandemic response, rapid and accurate diagnostic testing remains an often neglected cornerstone of pandemic influenza preparedness. Clinicians and Public Health Practitioners need to understand the benefits and drawbacks of different influenza tests in both seasonal and pandemic settings. Culture has been the traditional gold standard for influenza diagnosis but requires from 1-10 days to generate a positive result, compared to nucleic acid detection methods such as real time reverse transcriptase polymerase chain reaction (RT-PCR). Although the currently available rapid antigen detection kits can generate results in less than 30 minutes, their sensitivity is suboptimal and they are not recommended for the detection of novel influenza viruses. Until point-of-care (POC) tests are improved, PILPN recommends that the best option for pandemic influenza preparation is the enhancement of nucleic acid-based testing capabilities across Canada.
    Canadian journal of public health. Revue canadienne de santé publique 100(3):204-7. · 1.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The literature published on point-of-care testing between January 1, 2013, and December 31, 2013, was reviewed. Point-of-care testing is increasingly utilized in health care because of its availability as well as the industries’ response to demands for new testing and improvements to existing testing, its promise of rapid bedside results, its potential to reduce health care costs, and its ability to improve health care, particularly internationally. This review divides recent literature into categories that have been published most extensively in the past year and briefly describes select articles within each category. The categories include infectious disease/global health, obstetrics and gynecology, diabetes, technological advancements, and other topics including cardiac disease, coagulopathology, and toxicology.
    Point of Care The Journal of Near-Patient Testing & Technology 05/2007; 6(2):144-146. DOI:10.1097/01.poc.0000271406.37807.c1
Show more


7 Reads